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INTRODUCTION
Voriconazole is an azole antifungal agent active
against Candida species, Cryptococcus species,
Aspergillus species, Scedosporium apiospermum
and other less common pathogens. The approved
indications in Europe are the treatment of (i)
invasive aspergillosis; (ii) candidaemia in non-
neutropenic patients; (iii) serious invasive cand-
idosis due to ﬂuconazole-resistant Candida species
(including Candida krusei); and (iv) serious inva-
sive fungal disease caused by Scedosporium spp.
and Fusarium spp.
The activity in vitro of voriconazole against
species of Candida is not uniform. The species
most frequently involved in causing human
infections - Candida albicans, Candida parapsilosis,
Candida tropicalis, Candida glabrata and C. krusei -
usually exhibit MICs of voriconazole of less than
1 mg ⁄L. However the MICs of voriconazole for
ﬂuconazole-resistant isolates are proportionally
higher than are those of ﬂuconazole-susceptible
isolates. Therefore, every attempt should be made
to identify Candida to species level.
The Subcommittee on Antifungal Susceptibility
Testing (AFST) of the European Committee for
Antimicrobial Susceptibility Testing (EUCAST)
has determined breakpoints for voriconazole for
Candida species. These breakpoints are tentative
and will be reviewed after two years. This Techni-
cal Note is based on the EUCAST voriconazole
rationale document which provides more detail
and published references related to the selection
of EUCAST-AFST breakpoints (available on the
EUCAST website: http://www.eucast.org).
DOSAGE
The EUCAST-AFST has determined clinical
breakpoints for intravenous and oral doses. The
intravenous dose of voriconazole for adults is
12 mg ⁄ kg ⁄day on the ﬁrst day followed by
8 mg ⁄ kg ⁄day.
Oral doses are dependant on weight. Patients
weighing >40 kg are given 400 mg twice daily on
the ﬁrst day followed by 200 mg twice daily.
Patients weighing <40 kg are given 200 mg twice
daily on the ﬁrst day followed by 100 mg twice
daily.
MIC DISTRIBUTIONS
The MIC values for wild-type Candida spp are
shown in Table 1. The MIC distributions are
based on the MIC values obtained with EUCAST,
CLSI and E-test methods on and applied to large
collections of strains from several investigators.
Wild-type isolates of C. albicans, C. tropicalis and
C. parapsilosis exhibit MICs of £0.125 mg ⁄L,
whereas MICs for C. glabrata and C. krusei are
higher (commonly £1 mg ⁄L. Updates on wild-
type MIC distributions can be found at the
EUCAST website (http://www.eucast.org).
ESTABLISHED BREAKPOINTS
No European country has established national
breakpoints for voriconazole.
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PHARMACOKINETIC DATA
The pharmacokinetic data used to evaluate
voriconazole were based on standard doses
(Table 2). However the pharmacokinetics of
voriconazole are non-linear and variable and the
coefﬁcient of variation of the AUC has been
estimated to be 74–100%. Concentrations in
plasma vary >100-fold among subjects (based on
trough concentrations), depending partly on the
CYP2C19 genotype of the hepatic cytochrome
P450. CYP2C19 exhibits genetic polymorphism
resulting in an approximately four-fold higher
exposure in poor metabolizers than in extensive
metabolisers.
PHARMACODYNAMIC DATA
The fAUC ⁄MIC is the pharmacodynamic index
best related to outcome. In an experimental model
of murine candidosis a fAUC ⁄MIC of 24 ± 17
(mean ± SD) was sufﬁcient to achieve a reduction
of approximately 1.5 log10 CFU per kidney after
24 h of treatment. Monte Carlo simulations
showed that a target fAUC ⁄MIC of 24 would
inhibit 99% of isolates with an MIC £0.5 mg ⁄L if
treatment were given intravenously and 99% of
isolates with MIC £0.25 mg ⁄L if treatment were
given orally.
CLINICAL EFFICACY
Clinical data have been obtained from Pﬁzer
studies 608 (Global Candidemia Study), 603
(Empirical Therapy Study), 309 ⁄ 604 (Global Rare
and Refractory Studies), 301 (Compassionate Use
Protocol), and 606 (Emergency Use Protocol-U.S.
and Canada). The response exceeded 72% for
infections due to every species except C. glabrata
where the response was only 55%. Geometric
MICs were below 0.25 mg ⁄L except for C. glabrata
and C. krusei. CART analysis of the response
vs MIC or Log2MIC yielded a MIC value that
allowed discrimination between successes and
failures. However, the statistical support for this
classiﬁcation tree was limited as the relative risk
was 1.09, the area under ROC curve was only
0.6 and the false positive rate exceeded 50%.
CART analysis was also undertaken separately
for infections due to C. glabrata because of the
lower response rate but it failed to produce a
valid result. Hence, there was insufﬁcient evi-
dence found for any correlation between MIC
and clinical outcome.
Although the data are limited, it has been
shown that there is a decrease in the clinical
response of patients when voriconazole trough
blood levels are below 1 mg ⁄L. Conversely,
voriconazole trough blood levels above
5.5 mg ⁄L have been associated with an increase
in toxicity. Others report a favourable res-
ponse when random voriconazole blood con-
centrations exceed 2.05 mg ⁄L. This suggests
a potential role for monitoring blood concentra-
tions of voriconazole but further studies are
required.
Table 1. Voriconazole MIC distributionsa for Candida spp
Species
Number of isolates with indicated MIC (mg ⁄L)
ECOFF£ (mg ⁄L)b0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64
Candida albicans 50 996 5139 5235 1107 530 207 106 63 42 18 13 18 22 78 6 0.125
Candida glabrata 0 5 26 63 192 534 1218 1244 781 341 196 139 69 20 2 6 1
Candida krusei 0 0 2 10 23 29 152 489 424 119 30 10 1 0 0 0 1
Candida parapsilosis 0 6 287 1326 510 197 123 77 23 16 3 2 1 0 0 0 0.125
Candida tropicalis 0 28 133 602 934 732 274 113 51 32 8 2 10 20 16 3 0.125
aMICs determined according to EUCAST, CLSI and Etest methods are included in the distributions. Separate distributions for the three methods are shown on http://
www.eucast.org. bECOFF, epidemiological cut-off value (mg ⁄L) as deﬁned by EUCAST.
Table 2. Pharmacokinetic data for voriconazole
Parameter
Dosage
6 mg ⁄kg iv · 2
on day 1; maintenance
dose 4 mg ⁄kg · 2
Steady state
in patients with venous
haemoﬁltration
400 mg oral · 2
on day 1; maintenance
dose 200 mg · 2
Cmax (mg ⁄L) 5.9 ± 2.9 2–2.3
Cmin (mg ⁄L) 1.1 ± 0.3 NA
Total body clearance (L ⁄h) 12.9 ± 6.7 19.9
T½ (h), mean (range) 6 6
AUC24h (mg.h ⁄L) 44.8 18–22
Fraction unbound (%) 42 42
Volume of distribution (L ⁄ kg) 4.6 NA
NA, Not available
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BREAKPOINTS
Breakpoints are summarised in Table 3.
Non-species-related breakpoints
Non-species related breakpoints are determined
mainly on the basis of PK ⁄PD data and are
independent of MIC distributions of speciﬁc
species. They are for use only for species not
mentioned in the table or footnotes. In the case of
voriconazole, the pharmacokinetics are variable
and the clinical data on species other than C.
albicans, C. parapsilosis and C. tropicalis, and on
isolates with higher MICs, are scarce. Therefore
non-species related breakpoints have not been set
for voriconazole.
Species-related breakpoints
A clinical response of 76% has been achieved for
infections due to the species listed in Table 3
when MICs were lower than, or equal to, the
epidemiological cut-offs. Wild-type populations
of C. albicans, C. tropicalis and C. parapsilosis were
therefore considered to be susceptible to vorico-
nazole. Monte Carlo simulations showed that a
target attainment of 24 would encompass more
than 99% of the population for an MIC of
£0.125 mg ⁄L. There is insufﬁcient information
on the response to voriconazole treatment in
infections caused by Candida isolates with higher
MICs.
Strains with MIC values above the S ⁄ I break-
point are rare and the identiﬁcation and antimi-
crobial susceptibility testing of any such isolate
must be repeated and, if the result is conﬁrmed,
the isolate should be sent to a reference laboratory
for further investigation.
Species without breakpoints
Clinical studies of invasive candidosis caused by
C. glabrata, have shown a 21% lower response to
voriconazole compared with the response of
infections caused by C. albicans, C. parapsilosis or
C. tropicalis. CART analysis of outcome versus
MIC did not ﬁnd higher MICs to be the explana-
tion for the lower response. Consequently, clinical
breakpoints for C. glabrata will not be set unless
more data become available. The clinical response
of infections caused by C. krusei is similar to that
of infections caused by C. albicans, C. parapsilosis
and C. tropicalis.However, as there were only nine
cases available for analysis, clinical breakpoints
have not been set for C. krusei.
Table 3. EUCAST clinical MIC breakpoints for voriconazole, 2008
Species-related breakpoints (S£ ⁄R>)
Non-species-related breakpoints S£ ⁄R>C. albicans C. tropicalis C. parapsilosis C. glabrata C. krusei
Voriconazole 0.125 ⁄ 0.125a 0.125 ⁄ 0.125a 0.125 ⁄ 0.125a IE IE Noteb
IE, there is insufﬁcient evidence that the species in question is a good target for therapy with voriconazole.
aStrains with MIC values above the S ⁄ I breakpoint are rare or not yet reported. The identiﬁcation and antimicrobial susceptibility tests on any such isolate must be repeated
and, if the result is conﬁrmed, the isolate sent to a reference laboratory. A MIC above the current resistant breakpoint (in italics) should be considered resistant until more is
known about the clinical response of infections due to such isolates. bThe currently available data would suggest a non-species-related breakpoint of 0.25 mg ⁄L but
pharmacokinetics are variable and clinical data on species ⁄ isolates with MICs in the range 0.25–1 mg ⁄L are scarce. Non-species-related breakpoints have therefore not been set
at this time.
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